Palvella wins U.S. patent for topical statin treatment in porokeratosis, including DSAP

Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLA

0.00
  • Palvella Therapeutics secured a Yale-licensed U.S. patent covering topical HMG-CoA reductase inhibitors, including pitavastatin, for porokeratosis.
  • Patent protection runs into 2043, strengthening IP around its investigational QTORIN pitavastatin program for disseminated superficial actinic porokeratosis.
  • Phase 2 trial in DSAP planned for the second half of 2026, targeting a rare premalignant skin disease with no FDA-approved therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605270730PRIMZONEFULLFEED9727282) on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.